<DOC>
	<DOCNO>NCT00643968</DOCNO>
	<brief_summary>Primary objective : Evaluation efficacy TDF+3TC+EFV versus TDF+EFV QD maintain plasma HIV-1 RNA BLQ ( &lt; 50 copies/mL ) ( c/mL ) 48 week ( W48 ) Main Secondary objective : Comparison two arm genotypic resistance profile case virological failure CD4 change baseline Evolution lipid profile morphological change fat distribution , safety Efficacy genotypic profile data , result lipid marker , morphological change main biological parameter</brief_summary>
	<brief_title>Tenofovir DF + Efavirenz ( TDF+EFV ) Versus Tenofovir DF + Efavirenz + Lamivudine ( TDF+EFV+3TC ) Maintenance Regimen Virologically Controlled Patients : COOL Trial</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Stable HAART ≥ 3 month HIV1 RNA &lt; 50 c/mL ≥ 6 month No HAART failure history Weight &gt; 45 kg No CD4+ cell count criteria No significant laboratory clinical abnormality Creatinine Clearance &gt; 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>HIV virological control</keyword>
	<keyword>Lipid profile morphological fat distribution</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>